Literature DB >> 30776417

HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.

Katherine C Konvinse1, Jason A Trubiano2, Rebecca Pavlos3, Ian James4, Christian M Shaffer5, Cosmin A Bejan6, Ryan J Schutte7, David A Ostrov7, Mark A Pilkinton8, Misha Rosenbach9, Jeffrey P Zwerner10, Kristina B Williams8, Jack Bourke11, Patricia Martinez12, Francois Rwandamuriye4, Abha Chopra4, Mark Watson4, Alec J Redwood4, Katie D White8, Simon A Mallal13, Elizabeth J Phillips14.   

Abstract

BACKGROUND: Vancomycin is a prevalent cause of the severe hypersensitivity syndrome drug reaction with eosinophilia and systemic symptoms (DRESS), which leads to significant morbidity and mortality and commonly occurs in the setting of combination antibiotic therapy, affecting future treatment choices. Variations in HLA class I in particular have been associated with serious T cell-mediated adverse drug reactions, which has led to preventive screening strategies for some drugs.
OBJECTIVE: We sought to determine whether variation in the HLA region is associated with vancomycin-induced DRESS.
METHODS: Probable vancomycin-induced DRESS cases were matched 1:2 with tolerant control subjects based on sex, race, and age by using BioVU, Vanderbilt's deidentified electronic health record database. Associations between DRESS and carriage of HLA class I and II alleles were assessed by means of conditional logistic regression. An extended sample set from BioVU was used to conduct a time-to-event analysis of those exposed to vancomycin with and without the identified HLA risk allele.
RESULTS: Twenty-three subjects met the inclusion criteria for vancomycin-associated DRESS. Nineteen (82.6%) of 23 cases carried HLA-A*32:01 compared with 0 (0%) of 46 of the matched vancomycin-tolerant control subjects (P = 1 × 10-8) and 6.3% of the BioVU population (n = 54,249, P = 2 × 10-16). Time-to-event analysis of DRESS development during vancomycin treatment among the HLA-A*32:01-positive group indicated that 19.2% had DRESS and did so within 4 weeks.
CONCLUSIONS: HLA-A*32:01 is strongly associated with vancomycin-induced DRESS in a population of predominantly European ancestry. HLA-A*32:01 testing could improve antibiotic safety, help implicate vancomycin as the causal drug, and preserve future treatment options with coadministered antibiotics.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T-cell hypersensitivity; Vancomycin; antibiotic allergy; delayed hypersensitivity; drug reaction with eosinophilia and systemic symptoms; human leukocyte antigen

Mesh:

Substances:

Year:  2019        PMID: 30776417      PMCID: PMC6612297          DOI: 10.1016/j.jaci.2019.01.045

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  28 in total

1.  Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics.

Authors:  Raquel Empedrad; Amy Liebl Darter; Harry S Earl; Rebecca S Gruchalla
Journal:  J Allergy Clin Immunol       Date:  2003-09       Impact factor: 10.793

2.  Medical genetics: a marker for Stevens-Johnson syndrome.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

3.  Protein structure homology modeling using SWISS-MODEL workspace.

Authors:  Lorenza Bordoli; Florian Kiefer; Konstantin Arnold; Pascal Benkert; James Battey; Torsten Schwede
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

4.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors:  S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

5.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

Review 6.  Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome.

Authors:  Pierre-Dominique Ghislain; Jean-Claude Roujeau
Journal:  Dermatol Online J       Date:  2002-06

Review 7.  Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes.

Authors:  Noriko Aota; Tetsuo Shiohara
Journal:  Autoimmun Rev       Date:  2009-02-23       Impact factor: 9.754

8.  MHC motif viewer.

Authors:  Nicolas Rapin; Ilka Hoof; Ole Lund; Morten Nielsen
Journal:  Immunogenetics       Date:  2008-09-03       Impact factor: 2.846

9.  Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.

Authors:  Annalise M Martin; David Nolan; Silvana Gaudieri; Coral Ann Almeida; Richard Nolan; Ian James; Filipa Carvalho; Elizabeth Phillips; Frank T Christiansen; Anthony W Purcell; James McCluskey; Simon Mallal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

10.  HLA-B*5701 screening for hypersensitivity to abacavir.

Authors:  Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

View more
  38 in total

1.  Pharmacogenetics: Chasing Perfection.

Authors:  Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-08       Impact factor: 6.875

2.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms.

Authors:  Jason A Trubiano; David A Ostrov; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2019 Nov - Dec

3.  A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms.

Authors:  Francois X Rwandamuriye; Abha Chopra; Katherine C Konvinse; Linda Choo; Jason A Trubiano; Christian M Shaffer; Mark Watson; Simon A Mallal; Elizabeth J Phillips
Journal:  J Mol Diagn       Date:  2019-05-31       Impact factor: 5.568

Review 4.  Immune-mediated adverse reactions to vaccines.

Authors:  Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2019-11-05       Impact factor: 4.335

5.  SJS/TEN 2019: From science to translation.

Authors:  Wan-Chun Chang; Riichiro Abe; Paul Anderson; Wanpen Anderson; Michael R Ardern-Jones; Thomas M Beachkofsky; Teresa Bellón; Agnieszka K Biala; Charles Bouchard; Gianpiero L Cavalleri; Nicole Chapman; James Chodosh; Hyon K Choi; Ricardo R Cibotti; Sherrie J Divito; Karen Dewar; Ulrike Dehaeck; Mahyar Etminan; Diane Forbes; Esther Fuchs; Jennifer L Goldman; James H Holmes; Elyse A Hope; Shuen-Iu Hung; Chia-Ling Hsieh; Alfonso Iovieno; Julienne Jagdeo; Mee Kum Kim; David M Koelle; Mario E Lacouture; Sophie Le Pallec; Rannakoe J Lehloenya; Robyn Lim; Angie Lowe; Jean McCawley; Julie McCawley; Robert G Micheletti; Maja Mockenhaupt; Katie Niemeyer; Michael A Norcross; Douglas Oboh; Cristina Olteanu; Helena B Pasieka; Jonathan Peter; Munir Pirmohamed; Michael Rieder; Hajirah N Saeed; Neil H Shear; Christine Shieh; Sabine Straus; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Sheng-Ying Tsou; Mayumi Ueta; Simona Volpi; Chen Wan; Hongsheng Wang; Zhao-Qing Wang; Jessica Weintraub; Cindy Whale; Lisa M Wheatley; Sonia Whyte-Croasdaile; Kristina B Williams; Galen Wright; Sonia N Yeung; Li Zhou; Wen-Hung Chung; Elizabeth J Phillips; Bruce C Carleton
Journal:  J Dermatol Sci       Date:  2020-03-07       Impact factor: 4.563

6.  Vancomycin-induced drug rash with eosinophilia and systemic symptoms (DRESS).

Authors:  Kyle Yuan; Kanwal S Awan; James Long
Journal:  BMJ Case Rep       Date:  2020-02-04

7.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

8.  Development of a System for Postmarketing Population Pharmacokinetic and Pharmacodynamic Studies Using Real-World Data From Electronic Health Records.

Authors:  Leena Choi; Cole Beck; Elizabeth McNeer; Hannah L Weeks; Michael L Williams; Nathan T James; Xinnan Niu; Bassel W Abou-Khalil; Kelly A Birdwell; Dan M Roden; C Michael Stein; Cosmin A Bejan; Joshua C Denny; Sara L Van Driest
Journal:  Clin Pharmacol Ther       Date:  2020-02-11       Impact factor: 6.875

Review 9.  Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions.

Authors:  Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Jason B Giles; Jason H Karnes; Andrew Gibson; Elizabeth J Phillips
Journal:  Clin Pharmacol Ther       Date:  2021-07-17       Impact factor: 6.875

10.  Vancomycin Hypersensitivity Reactions Documented in Electronic Health Records.

Authors:  Santiago Alvarez-Arango; Sharmitha Yerneni; Olive Tang; Li Zhou; Christian M Mancini; Suzanne V Blackley; Corinne Allison Keet; Kimberly G Blumenthal
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.